Markets

Ionis Pharmaceuticals Receives EMA CHMP Positive Opinion Recommending Indication Extension For TRYNGOLZA For Treatment Of Adult Patients With Severe Hypertriglyceridemia

Oct 16, 2026 · 06:48 AM ET· updated 1h ago

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication

Why It Matters

Ionis got approval to treat more patients with its heart medicine. Watch for expanded sales and whether other countries follow Europe's approval.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

IONS43.56

+0.86 (+2.01%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.